taldefgrobep alfa

DRUG2 trials

Sponsors

Biohaven Pharmaceuticals, Inc., Biohaven Therapeutics Ltd.

Conditions

Neuromuscular DiseasesObesityOverweightSMASpinal Muscular Atrophy

Phase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Active, not recruitingNCT07281495

Biohaven Therapeutics Ltd.Obesity, Overweight

Start: 2025-11-24End: 2026-09-01Target: 150Updated: 2026-03-20

Phase 3

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Active, not recruitingNCT05337553

Biohaven Pharmaceuticals, Inc.Neuromuscular Diseases, SMA, Spinal Muscular Atrophy

Start: 2022-07-06End: 2027-12-01Updated: 2026-06-01

Related Papers

Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.

2024-09-249 citations